UroGen Pharma's ZUSDURI Soars, Driving Q1 Revenue

UroGen Pharmas Q1 2026 results are impressive, with total revenue surging by 152% to $51 million, driven by ZUSDURIs bladder cancer treatment. The drugs permanent J-code implementation in January led to a significant sales boost, with prescribers increasing from 102 to 256 and repeat users from 32 to 103. ZUSDURIs popularity is growing, outpacing JELMYTO, and its gaining traction in community clinics. The CEOs direct involvement in commercial operations and a strong pipeline position UroGen for a five billion dollar market, with blockbuster potential. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/5f8f673fef28cc46